知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1458 条记录 (耗时 0.03 秒)

    Kaposi sarcoma associated herpesvirus gene function
    6.
    发明公开
    Kaposi sarcoma associated herpesvirus gene function 审中-公开

    公开(公告)号：US20240248080A1

    公开(公告)日：2024-07-25

    申请号：US18629922

    申请日：2024-04-08

    申请人： The Regents of the University of California

    发明人： Fenyong Liu ,  Adam Smith ,  Marco Paliza-Carre ,  Rachael Burchfield

    IPC分类号： G01N33/50 ,  A61K39/00 ,  A61K39/245 ,  C07K14/005 ,  C12N7/00

    CPC分类号： G01N33/5091 ,  A61K39/245 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/80 ,  C12N2710/16022 ,  C12N2710/16052 ,  G01N2333/03

    摘要： Kaposi's sarcoma-associated herpesvirus (KSHV) is an opportunistic pathogen causing Kaposi's sarcoma. It is capable of establishing latent infection, which can be reactivated to engage lytic infection for progeny production. KSHV contains a ˜165 kilobase DNA genome predicted to encode at least 90 open reading frames (ORFs). In this report, we generated 91 KSHV mutants, each characterized by the disruption of a single viral ORF. The growth of these mutants in cultured cells was examined to systematically investigate the necessity of each ORF for viral latency, reactivation, and lytic replication. Salient aspects are (a) 44 ORFs are essential for viral lytic replication in cultured cells and 47 are nonessential; (b) KSHV reactivation can be positively or negatively regulated by specific viral ORFs; and (c) ORFs identified to regulate viral reactivation encode functions modulating both innate and adaptive immune responses. The intersection of viral immunomodulatory genes controlling reactivation suggests that KSHV engages in a concerted effort to communicate and respond to the host immune system for reactivation and replication using a viral sensory network. Our results imply a novel mechanism in which reactivation of KSHV is actively controlled by the virus in response to its surrounding environment, leading to the opportunistic nature of viral diseases that are strongly correlated to the host's immune status and conditions.

    THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF
    7.
    发明公开
    THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF 审中-公开

    公开(公告)号：US20240199724A1

    公开(公告)日：2024-06-20

    申请号：US18272255

    申请日：2022-01-28

    申请人： THELPER AS

    发明人： Katja Vetvik

    IPC分类号： C07K16/08 ,  A61K39/00 ,  A61K39/245 ,  A61K47/68 ,  A61P31/22 ,  C07K14/74 ,  C12N15/63

    CPC分类号： C07K16/089 ,  A61K39/245 ,  A61K47/68 ,  A61P31/22 ,  C07K14/70539 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2319/30

    摘要： The present invention provides binding molecules having one or more of (preferably all of) highly specific binding to the US28 protein of human cytomegalovirus (HCMV), very low levels of non-specific binding to healthy (non-infected) cells, and/or a strain-agnostic binding ability, as well as nucleic acid molecules encoding the said binding molecules. The binding molecules are designed to bind to extracellular domain 3 (ECD3) of a US28 protein of human cytomegalovirus (HCMV), the third of the four extracellular domains presented by US28, corresponding to positions 167 to 183 of the US28 protein sequence as defined by SEQ ID NO:5. The binding molecules of the present invention have been demonstrated to have excellent binding properties, including particular binding specificity for aggressive and/or metastasizing HCMV-infected cancers, including breast cancers. In certain preferred embodiments, the binding molecule is selected from an antibody (including, for example, a BiTE antibody) and a chimeric antigen receptor (CAR), or functional variants, fragments, fusion proteins, and/or conjugates thereof. Also provided are cells expressing said binding molecules, such as CAR-expressing cells, including CAR-T cells, CAR-NK cells, and CAR-M cells.